Imunon, Inc.
IMNN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.03 | -1.50 | 0.06 |
| FCF Yield | -8,855.93% | -16.84% | -17.67% | -28.00% |
| EV / EBITDA | -0.33 | -5.47 | -3.98 | -2.85 |
| Quality | ||||
| ROIC | 91.38% | -65.35% | -223.47% | -77.02% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.30 | 1.08 | 0.69 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -44,952.64% | 4.44% | 29.96% | -9.30% |
| Safety | ||||
| Net Debt / EBITDA | -0.32 | 1.37 | 0.47 | 1.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -948.55 | -845.13 | -321.81 |